nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—liver cancer—stomach cancer	0.491	1	CtDrD
Sorafenib—RALBP1—Doxorubicin—stomach cancer	0.0506	0.199	CbGbCtD
Sorafenib—UGT1A9—Irinotecan—stomach cancer	0.0195	0.0766	CbGbCtD
Sorafenib—UGT1A1—Irinotecan—stomach cancer	0.016	0.0627	CbGbCtD
Sorafenib—ABCC4—Fluorouracil—stomach cancer	0.0157	0.0615	CbGbCtD
Sorafenib—ABCB1—Mitomycin—stomach cancer	0.0123	0.0485	CbGbCtD
Sorafenib—ABCC2—Irinotecan—stomach cancer	0.00971	0.0381	CbGbCtD
Sorafenib—ABCG2—Irinotecan—stomach cancer	0.00878	0.0345	CbGbCtD
Sorafenib—ABCC4—Methotrexate—stomach cancer	0.00864	0.0339	CbGbCtD
Sorafenib—ABCG2—Fluorouracil—stomach cancer	0.00843	0.0331	CbGbCtD
Sorafenib—ABCC2—Docetaxel—stomach cancer	0.00712	0.0279	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Irinotecan—stomach cancer	0.00649	0.0255	CbGbCtD
Sorafenib—CYP3A7—Irinotecan—stomach cancer	0.00649	0.0255	CbGbCtD
Sorafenib—ABCG2—Docetaxel—stomach cancer	0.00644	0.0253	CbGbCtD
Sorafenib—CYP2B6—Irinotecan—stomach cancer	0.00618	0.0242	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—stomach cancer	0.00531	0.0208	CbGbCtD
Sorafenib—CYP2C9—Capecitabine—stomach cancer	0.00528	0.0207	CbGbCtD
Sorafenib—ABCC2—Methotrexate—stomach cancer	0.00514	0.0202	CbGbCtD
Sorafenib—CYP3A5—Irinotecan—stomach cancer	0.00487	0.0191	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—stomach cancer	0.0048	0.0188	CbGbCtD
Sorafenib—CYP3A7—Docetaxel—stomach cancer	0.00475	0.0187	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Docetaxel—stomach cancer	0.00475	0.0187	CbGbCtD
Sorafenib—ABCG2—Methotrexate—stomach cancer	0.00465	0.0182	CbGbCtD
Sorafenib—CYP2C8—Fluorouracil—stomach cancer	0.00449	0.0176	CbGbCtD
Sorafenib—CYP3A5—Docetaxel—stomach cancer	0.00357	0.014	CbGbCtD
Sorafenib—CYP1A2—Fluorouracil—stomach cancer	0.00348	0.0136	CbGbCtD
Sorafenib—CYP2B6—Doxorubicin—stomach cancer	0.00337	0.0132	CbGbCtD
Sorafenib—ABCB1—Irinotecan—stomach cancer	0.00317	0.0124	CbGbCtD
Sorafenib—CYP2C9—Fluorouracil—stomach cancer	0.00313	0.0123	CbGbCtD
Sorafenib—ABCB1—Docetaxel—stomach cancer	0.00232	0.00911	CbGbCtD
Sorafenib—KIT—myenteric nerve plexus—stomach cancer	0.00227	0.0394	CbGeAlD
Sorafenib—CYP3A4—Irinotecan—stomach cancer	0.0019	0.00745	CbGbCtD
Sorafenib—Regorafenib—FGFR2—stomach cancer	0.00182	0.902	CrCbGaD
Sorafenib—ABCB1—Doxorubicin—stomach cancer	0.00173	0.00679	CbGbCtD
Sorafenib—ABCB1—Methotrexate—stomach cancer	0.00168	0.00658	CbGbCtD
Sorafenib—CYP2D6—Doxorubicin—stomach cancer	0.00163	0.0064	CbGbCtD
Sorafenib—CYP3A4—Docetaxel—stomach cancer	0.00139	0.00546	CbGbCtD
Sorafenib—ABCC2—bile—stomach cancer	0.00118	0.0205	CbGeAlD
Sorafenib—CYP3A4—Doxorubicin—stomach cancer	0.00104	0.00407	CbGbCtD
Sorafenib—TIE1—blood vessel—stomach cancer	0.000963	0.0167	CbGeAlD
Sorafenib—RAF1—Topotecan—Irinotecan—stomach cancer	0.000809	0.359	CbGdCrCtD
Sorafenib—FLT4—blood vessel—stomach cancer	0.000796	0.0138	CbGeAlD
Sorafenib—CDKL3—endocrine gland—stomach cancer	0.000776	0.0135	CbGeAlD
Sorafenib—CDKL2—endocrine gland—stomach cancer	0.00071	0.0123	CbGeAlD
Sorafenib—CDK7—hematopoietic system—stomach cancer	0.000649	0.0113	CbGeAlD
Sorafenib—MAPK15—endocrine gland—stomach cancer	0.000639	0.0111	CbGeAlD
Sorafenib—FLT1—blood vessel—stomach cancer	0.000619	0.0107	CbGeAlD
Sorafenib—CDK7—Topotecan—Irinotecan—stomach cancer	0.000613	0.272	CbGdCrCtD
Sorafenib—ZAK—hematopoietic system—stomach cancer	0.000561	0.00974	CbGeAlD
Sorafenib—PDGFRA—gall bladder—stomach cancer	0.000546	0.00948	CbGeAlD
Sorafenib—KDR—blood vessel—stomach cancer	0.000523	0.00909	CbGeAlD
Sorafenib—TIE1—hematopoietic system—stomach cancer	0.000513	0.00891	CbGeAlD
Sorafenib—TIE1—epithelium—stomach cancer	0.000469	0.00814	CbGeAlD
Sorafenib—FLT3—hematopoietic system—stomach cancer	0.000467	0.00811	CbGeAlD
Sorafenib—KIT—blood vessel—stomach cancer	0.000464	0.00805	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—stomach cancer	0.000457	0.00793	CbGeAlD
Sorafenib—PDGFRB—blood vessel—stomach cancer	0.000453	0.00786	CbGeAlD
Sorafenib—TIE1—smooth muscle tissue—stomach cancer	0.000452	0.00785	CbGeAlD
Sorafenib—HIPK3—pancreas—stomach cancer	0.000447	0.00776	CbGeAlD
Sorafenib—KIT—gall bladder—stomach cancer	0.000436	0.00758	CbGeAlD
Sorafenib—HIPK4—endocrine gland—stomach cancer	0.00043	0.00747	CbGeAlD
Sorafenib—PDGFRB—gall bladder—stomach cancer	0.000426	0.0074	CbGeAlD
Sorafenib—FLT4—hematopoietic system—stomach cancer	0.000424	0.00736	CbGeAlD
Sorafenib—ZAK—lymphoid tissue—stomach cancer	0.000395	0.00686	CbGeAlD
Sorafenib—ZAK—digestive system—stomach cancer	0.00039	0.00677	CbGeAlD
Sorafenib—FLT4—epithelium—stomach cancer	0.000388	0.00673	CbGeAlD
Sorafenib—MKNK2—hematopoietic system—stomach cancer	0.000384	0.00666	CbGeAlD
Sorafenib—HIPK3—digestive system—stomach cancer	0.000382	0.00663	CbGeAlD
Sorafenib—MKNK1—hematopoietic system—stomach cancer	0.000379	0.00658	CbGeAlD
Sorafenib—RET—hematopoietic system—stomach cancer	0.000374	0.0065	CbGeAlD
Sorafenib—CDK7—endocrine gland—stomach cancer	0.000373	0.00648	CbGeAlD
Sorafenib—AURKC—endocrine gland—stomach cancer	0.000367	0.00638	CbGeAlD
Sorafenib—HIPK3—bone marrow—stomach cancer	0.000352	0.00611	CbGeAlD
Sorafenib—MKNK2—epithelium—stomach cancer	0.000351	0.00609	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—stomach cancer	0.000349	0.00606	CbGeAlD
Sorafenib—RALBP1—hematopoietic system—stomach cancer	0.000347	0.00602	CbGeAlD
Sorafenib—RET—epithelium—stomach cancer	0.000342	0.00594	CbGeAlD
Sorafenib—EPHA6—endocrine gland—stomach cancer	0.00034	0.0059	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—stomach cancer	0.000338	0.00587	CbGeAlD
Sorafenib—CDK7—liver—stomach cancer	0.000336	0.00584	CbGeAlD
Sorafenib—TAOK2—liver—stomach cancer	0.000334	0.00579	CbGeAlD
Sorafenib—FLT1—hematopoietic system—stomach cancer	0.00033	0.00572	CbGeAlD
Sorafenib—FLT3—lymphoid tissue—stomach cancer	0.000329	0.00571	CbGeAlD
Sorafenib—RAF1—hematopoietic system—stomach cancer	0.000328	0.00569	CbGeAlD
Sorafenib—ZAK—endocrine gland—stomach cancer	0.000322	0.0056	CbGeAlD
Sorafenib—HIPK3—endocrine gland—stomach cancer	0.000315	0.00548	CbGeAlD
Sorafenib—BRAF—bone marrow—stomach cancer	0.000315	0.00548	CbGeAlD
Sorafenib—MKNK2—pancreas—stomach cancer	0.000312	0.00543	CbGeAlD
Sorafenib—STK10—hematopoietic system—stomach cancer	0.000312	0.00542	CbGeAlD
Sorafenib—PDGFRA—hematopoietic system—stomach cancer	0.000309	0.00536	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—stomach cancer	0.000305	0.0053	CbGeAlD
Sorafenib—FLT1—epithelium—stomach cancer	0.000301	0.00523	CbGeAlD
Sorafenib—RAF1—epithelium—stomach cancer	0.0003	0.0052	CbGeAlD
Sorafenib—FLT3—bone marrow—stomach cancer	0.000299	0.0052	CbGeAlD
Sorafenib—UGT1A9—digestive system—stomach cancer	0.000299	0.00519	CbGeAlD
Sorafenib—FLT4—lymphoid tissue—stomach cancer	0.000298	0.00518	CbGeAlD
Sorafenib—UGT1A1—hematopoietic system—stomach cancer	0.000295	0.00512	CbGeAlD
Sorafenib—ZAK—liver—stomach cancer	0.000291	0.00505	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—stomach cancer	0.00029	0.00504	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—stomach cancer	0.000289	0.00501	CbGeAlD
Sorafenib—HIPK3—liver—stomach cancer	0.000284	0.00494	CbGeAlD
Sorafenib—RALBP1—pancreas—stomach cancer	0.000282	0.0049	CbGeAlD
Sorafenib—KDR—hematopoietic system—stomach cancer	0.000279	0.00484	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—stomach cancer	0.000272	0.00472	CbGeAlD
Sorafenib—CSF1R—hematopoietic system—stomach cancer	0.000272	0.00472	CbGeAlD
Sorafenib—FLT4—bone marrow—stomach cancer	0.000272	0.00472	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—stomach cancer	0.00027	0.00469	CbGeAlD
Sorafenib—FLT1—pancreas—stomach cancer	0.000268	0.00466	CbGeAlD
Sorafenib—FLT3—endocrine gland—stomach cancer	0.000268	0.00466	CbGeAlD
Sorafenib—MKNK2—digestive system—stomach cancer	0.000267	0.00463	CbGeAlD
Sorafenib—RAF1—pancreas—stomach cancer	0.000267	0.00463	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—stomach cancer	0.000267	0.00463	CbGeAlD
Sorafenib—TIE1—liver—stomach cancer	0.000266	0.00462	CbGeAlD
Sorafenib—MKNK1—digestive system—stomach cancer	0.000263	0.00458	CbGeAlD
Sorafenib—RET—lymphoid tissue—stomach cancer	0.000263	0.00458	CbGeAlD
Sorafenib—MAPK11—lymph node—stomach cancer	0.000262	0.00455	CbGeAlD
Sorafenib—RET—digestive system—stomach cancer	0.00026	0.00452	CbGeAlD
Sorafenib—CDK7—lymph node—stomach cancer	0.000258	0.00448	CbGeAlD
Sorafenib—TAOK2—lymph node—stomach cancer	0.000256	0.00444	CbGeAlD
Sorafenib—BRAF—liver—stomach cancer	0.000255	0.00443	CbGeAlD
Sorafenib—KDR—epithelium—stomach cancer	0.000255	0.00442	CbGeAlD
Sorafenib—MAP3K7—bone marrow—stomach cancer	0.000254	0.00441	CbGeAlD
Sorafenib—AURKC—lymph node—stomach cancer	0.000254	0.00441	CbGeAlD
Sorafenib—UGT1A9—endocrine gland—stomach cancer	0.000247	0.00429	CbGeAlD
Sorafenib—KIT—hematopoietic system—stomach cancer	0.000247	0.00429	CbGeAlD
Sorafenib—MKNK2—bone marrow—stomach cancer	0.000246	0.00427	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—stomach cancer	0.000245	0.00426	CbGeAlD
Sorafenib—FLT4—endocrine gland—stomach cancer	0.000244	0.00423	CbGeAlD
Sorafenib—EPHX2—liver—stomach cancer	0.000244	0.00423	CbGeAlD
Sorafenib—MKNK1—bone marrow—stomach cancer	0.000243	0.00422	CbGeAlD
Sorafenib—FLT3—liver—stomach cancer	0.000242	0.0042	CbGeAlD
Sorafenib—PDGFRB—hematopoietic system—stomach cancer	0.000241	0.00419	CbGeAlD
Sorafenib—RALBP1—digestive system—stomach cancer	0.000241	0.00419	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—stomach cancer	0.00024	0.00416	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—stomach cancer	0.000232	0.00403	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—stomach cancer	0.000231	0.00401	CbGeAlD
Sorafenib—FLT1—digestive system—stomach cancer	0.000229	0.00398	CbGeAlD
Sorafenib—RAF1—digestive system—stomach cancer	0.000228	0.00396	CbGeAlD
Sorafenib—KIT—epithelium—stomach cancer	0.000226	0.00392	CbGeAlD
Sorafenib—ZAK—lymph node—stomach cancer	0.000223	0.00387	CbGeAlD
Sorafenib—UGT1A9—liver—stomach cancer	0.000223	0.00387	CbGeAlD
Sorafenib—RALBP1—bone marrow—stomach cancer	0.000222	0.00386	CbGeAlD
Sorafenib—MKNK2—endocrine gland—stomach cancer	0.000221	0.00383	CbGeAlD
Sorafenib—PDGFRB—epithelium—stomach cancer	0.00022	0.00383	CbGeAlD
Sorafenib—STK10—lymphoid tissue—stomach cancer	0.00022	0.00381	CbGeAlD
Sorafenib—FLT4—liver—stomach cancer	0.00022	0.00381	CbGeAlD
Sorafenib—HIPK3—lymph node—stomach cancer	0.000218	0.00379	CbGeAlD
Sorafenib—MKNK1—endocrine gland—stomach cancer	0.000218	0.00378	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—stomach cancer	0.000217	0.00378	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—stomach cancer	0.000217	0.00378	CbGeAlD
Sorafenib—STK10—digestive system—stomach cancer	0.000217	0.00377	CbGeAlD
Sorafenib—FGFR1—liver—stomach cancer	0.000217	0.00376	CbGeAlD
Sorafenib—RET—endocrine gland—stomach cancer	0.000215	0.00373	CbGeAlD
Sorafenib—PDGFRA—digestive system—stomach cancer	0.000215	0.00373	CbGeAlD
Sorafenib—PDGFRB—smooth muscle tissue—stomach cancer	0.000212	0.00369	CbGeAlD
Sorafenib—RAF1—bone marrow—stomach cancer	0.00021	0.00365	CbGeAlD
Sorafenib—CYP3A7—endocrine gland—stomach cancer	0.000205	0.00357	CbGeAlD
Sorafenib—MAP3K7—liver—stomach cancer	0.000205	0.00356	CbGeAlD
Sorafenib—UGT1A1—digestive system—stomach cancer	0.000205	0.00356	CbGeAlD
Sorafenib—TIE1—lymph node—stomach cancer	0.000204	0.00354	CbGeAlD
Sorafenib—KIT—pancreas—stomach cancer	0.000201	0.00349	CbGeAlD
Sorafenib—STK10—bone marrow—stomach cancer	0.0002	0.00347	CbGeAlD
Sorafenib—RALBP1—endocrine gland—stomach cancer	0.000199	0.00346	CbGeAlD
Sorafenib—MKNK2—liver—stomach cancer	0.000199	0.00345	CbGeAlD
Sorafenib—Vismodegib—ALB—stomach cancer	0.000197	0.0977	CrCbGaD
Sorafenib—PDGFRB—pancreas—stomach cancer	0.000196	0.00341	CbGeAlD
Sorafenib—MKNK1—liver—stomach cancer	0.000196	0.00341	CbGeAlD
Sorafenib—KDR—lymphoid tissue—stomach cancer	0.000196	0.00341	CbGeAlD
Sorafenib—BRAF—lymph node—stomach cancer	0.000195	0.00339	CbGeAlD
Sorafenib—KDR—digestive system—stomach cancer	0.000194	0.00336	CbGeAlD
Sorafenib—ABCC4—hematopoietic system—stomach cancer	0.000192	0.00333	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—stomach cancer	0.000191	0.00332	CbGeAlD
Sorafenib—FLT1—endocrine gland—stomach cancer	0.000189	0.00329	CbGeAlD
Sorafenib—CSF1R—digestive system—stomach cancer	0.000189	0.00328	CbGeAlD
Sorafenib—RAF1—endocrine gland—stomach cancer	0.000188	0.00327	CbGeAlD
Sorafenib—EPHX2—lymph node—stomach cancer	0.000187	0.00324	CbGeAlD
Sorafenib—FLT3—lymph node—stomach cancer	0.000185	0.00322	CbGeAlD
Sorafenib—CYP3A7—liver—stomach cancer	0.000185	0.00322	CbGeAlD
Sorafenib—RALBP1—liver—stomach cancer	0.00018	0.00312	CbGeAlD
Sorafenib—STK10—endocrine gland—stomach cancer	0.000179	0.00311	CbGeAlD
Sorafenib—KDR—bone marrow—stomach cancer	0.000179	0.0031	CbGeAlD
Sorafenib—PDGFRA—endocrine gland—stomach cancer	0.000177	0.00308	CbGeAlD
Sorafenib—CSF1R—bone marrow—stomach cancer	0.000174	0.00303	CbGeAlD
Sorafenib—KIT—lymphoid tissue—stomach cancer	0.000174	0.00302	CbGeAlD
Sorafenib—KIT—digestive system—stomach cancer	0.000172	0.00298	CbGeAlD
Sorafenib—FLT1—liver—stomach cancer	0.000171	0.00297	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—stomach cancer	0.00017	0.00295	CbGeAlD
Sorafenib—RAF1—liver—stomach cancer	0.00017	0.00295	CbGeAlD
Sorafenib—UGT1A1—endocrine gland—stomach cancer	0.000169	0.00294	CbGeAlD
Sorafenib—FLT4—lymph node—stomach cancer	0.000168	0.00292	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—stomach cancer	0.000168	0.00292	CbGeAlD
Sorafenib—PDGFRB—digestive system—stomach cancer	0.000168	0.00291	CbGeAlD
Sorafenib—FGFR1—lymph node—stomach cancer	0.000166	0.00288	CbGeAlD
Sorafenib—STK10—liver—stomach cancer	0.000162	0.00281	CbGeAlD
Sorafenib—MAP2K5—endocrine gland—stomach cancer	0.00016	0.00278	CbGeAlD
Sorafenib—KDR—endocrine gland—stomach cancer	0.00016	0.00278	CbGeAlD
Sorafenib—PDGFRA—liver—stomach cancer	0.00016	0.00278	CbGeAlD
Sorafenib—CYP2C19—hematopoietic system—stomach cancer	0.00016	0.00277	CbGeAlD
Sorafenib—KIT—bone marrow—stomach cancer	0.000158	0.00275	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—liver—stomach cancer	0.000157	0.00274	CbGeAlD
Sorafenib—MAP3K7—lymph node—stomach cancer	0.000157	0.00273	CbGeAlD
Sorafenib—ABCC4—pancreas—stomach cancer	0.000156	0.00272	CbGeAlD
Sorafenib—CSF1R—endocrine gland—stomach cancer	0.000156	0.00271	CbGeAlD
Sorafenib—PDGFRB—bone marrow—stomach cancer	0.000155	0.00268	CbGeAlD
Sorafenib—UGT1A1—liver—stomach cancer	0.000153	0.00265	CbGeAlD
Sorafenib—MKNK2—lymph node—stomach cancer	0.000152	0.00265	CbGeAlD
Sorafenib—MKNK1—lymph node—stomach cancer	0.000151	0.00261	CbGeAlD
Sorafenib—RET—lymph node—stomach cancer	0.000149	0.00258	CbGeAlD
Sorafenib—MAP2K5—liver—stomach cancer	0.000144	0.00251	CbGeAlD
Sorafenib—KDR—liver—stomach cancer	0.000144	0.00251	CbGeAlD
Sorafenib—CDK7—Doxorubicin—Epirubicin—stomach cancer	0.000144	0.0639	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Epirubicin—stomach cancer	0.000144	0.0639	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Epirubicin—stomach cancer	0.000144	0.0639	CbGdCrCtD
Sorafenib—KIT—endocrine gland—stomach cancer	0.000142	0.00246	CbGeAlD
Sorafenib—CSF1R—liver—stomach cancer	0.000141	0.00245	CbGeAlD
Sorafenib—CYP2C8—hematopoietic system—stomach cancer	0.000139	0.00242	CbGeAlD
Sorafenib—PDGFRB—endocrine gland—stomach cancer	0.000139	0.00241	CbGeAlD
Sorafenib—RALBP1—lymph node—stomach cancer	0.000138	0.00239	CbGeAlD
Sorafenib—ABCC4—digestive system—stomach cancer	0.000134	0.00232	CbGeAlD
Sorafenib—CDK7—Epirubicin—Doxorubicin—stomach cancer	0.000133	0.0591	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—stomach cancer	0.000133	0.0591	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—stomach cancer	0.000133	0.0591	CbGdCrCtD
Sorafenib—HTR2B—digestive system—stomach cancer	0.000133	0.00231	CbGeAlD
Sorafenib—FLT1—lymph node—stomach cancer	0.000131	0.00227	CbGeAlD
Sorafenib—CYP1A2—hematopoietic system—stomach cancer	0.00013	0.00227	CbGeAlD
Sorafenib—RAF1—lymph node—stomach cancer	0.00013	0.00226	CbGeAlD
Sorafenib—EPHB6—lymph node—stomach cancer	0.000129	0.00225	CbGeAlD
Sorafenib—ABCC2—digestive system—stomach cancer	0.000129	0.00224	CbGeAlD
Sorafenib—KIT—liver—stomach cancer	0.000128	0.00222	CbGeAlD
Sorafenib—CYP3A5—hematopoietic system—stomach cancer	0.000126	0.00219	CbGeAlD
Sorafenib—ABCB1—blood vessel—stomach cancer	0.000126	0.00218	CbGeAlD
Sorafenib—CYP2B6—hematopoietic system—stomach cancer	0.000125	0.00217	CbGeAlD
Sorafenib—PDGFRB—liver—stomach cancer	0.000125	0.00217	CbGeAlD
Sorafenib—STK10—lymph node—stomach cancer	0.000124	0.00215	CbGeAlD
Sorafenib—CYP2C9—hematopoietic system—stomach cancer	0.000124	0.00215	CbGeAlD
Sorafenib—ABCC4—bone marrow—stomach cancer	0.000123	0.00214	CbGeAlD
Sorafenib—PDGFRA—lymph node—stomach cancer	0.000123	0.00213	CbGeAlD
Sorafenib—CYP2C19—digestive system—stomach cancer	0.000111	0.00193	CbGeAlD
Sorafenib—MAP2K5—lymph node—stomach cancer	0.000111	0.00192	CbGeAlD
Sorafenib—KDR—lymph node—stomach cancer	0.000111	0.00192	CbGeAlD
Sorafenib—ABCC4—endocrine gland—stomach cancer	0.00011	0.00192	CbGeAlD
Sorafenib—CSF1R—lymph node—stomach cancer	0.000108	0.00188	CbGeAlD
Sorafenib—ABCC2—endocrine gland—stomach cancer	0.000107	0.00185	CbGeAlD
Sorafenib—CYP3A5—pancreas—stomach cancer	0.000102	0.00178	CbGeAlD
Sorafenib—ABCC4—liver—stomach cancer	9.95e-05	0.00173	CbGeAlD
Sorafenib—KIT—lymph node—stomach cancer	9.81e-05	0.0017	CbGeAlD
Sorafenib—ABCC2—liver—stomach cancer	9.63e-05	0.00167	CbGeAlD
Sorafenib—PDGFRB—lymph node—stomach cancer	9.58e-05	0.00166	CbGeAlD
Sorafenib—CYP3A4—hematopoietic system—stomach cancer	9.44e-05	0.00164	CbGeAlD
Sorafenib—CYP2D6—hematopoietic system—stomach cancer	9.29e-05	0.00161	CbGeAlD
Sorafenib—CYP2C19—endocrine gland—stomach cancer	9.18e-05	0.00159	CbGeAlD
Sorafenib—CYP1A2—digestive system—stomach cancer	9.07e-05	0.00158	CbGeAlD
Sorafenib—CYP2B6—lymphoid tissue—stomach cancer	8.8e-05	0.00153	CbGeAlD
Sorafenib—CYP3A5—digestive system—stomach cancer	8.75e-05	0.00152	CbGeAlD
Sorafenib—CYP2B6—digestive system—stomach cancer	8.7e-05	0.00151	CbGeAlD
Sorafenib—ABCG2—bone marrow—stomach cancer	8.69e-05	0.00151	CbGeAlD
Sorafenib—CYP2C9—digestive system—stomach cancer	8.61e-05	0.0015	CbGeAlD
Sorafenib—CYP2C19—liver—stomach cancer	8.28e-05	0.00144	CbGeAlD
Sorafenib—CYP2C8—endocrine gland—stomach cancer	8.01e-05	0.00139	CbGeAlD
Sorafenib—ABCC4—lymph node—stomach cancer	7.63e-05	0.00132	CbGeAlD
Sorafenib—HTR2B—lymph node—stomach cancer	7.59e-05	0.00132	CbGeAlD
Sorafenib—CYP1A2—endocrine gland—stomach cancer	7.5e-05	0.0013	CbGeAlD
Sorafenib—ABCC2—lymph node—stomach cancer	7.38e-05	0.00128	CbGeAlD
Sorafenib—CYP3A5—endocrine gland—stomach cancer	7.23e-05	0.00126	CbGeAlD
Sorafenib—CYP2C8—liver—stomach cancer	7.22e-05	0.00125	CbGeAlD
Sorafenib—CYP2B6—endocrine gland—stomach cancer	7.19e-05	0.00125	CbGeAlD
Sorafenib—CYP2C9—endocrine gland—stomach cancer	7.12e-05	0.00124	CbGeAlD
Sorafenib—ABCG2—liver—stomach cancer	7.02e-05	0.00122	CbGeAlD
Sorafenib—CYP1A2—liver—stomach cancer	6.76e-05	0.00117	CbGeAlD
Sorafenib—ABCB1—hematopoietic system—stomach cancer	6.68e-05	0.00116	CbGeAlD
Sorafenib—CYP3A4—digestive system—stomach cancer	6.57e-05	0.00114	CbGeAlD
Sorafenib—CYP3A5—liver—stomach cancer	6.52e-05	0.00113	CbGeAlD
Sorafenib—CYP2B6—liver—stomach cancer	6.48e-05	0.00113	CbGeAlD
Sorafenib—CYP2D6—digestive system—stomach cancer	6.46e-05	0.00112	CbGeAlD
Sorafenib—CYP2C9—liver—stomach cancer	6.42e-05	0.00111	CbGeAlD
Sorafenib—ABCB1—epithelium—stomach cancer	6.11e-05	0.00106	CbGeAlD
Sorafenib—ABCB1—pancreas—stomach cancer	5.44e-05	0.000945	CbGeAlD
Sorafenib—CYP3A4—endocrine gland—stomach cancer	5.43e-05	0.000942	CbGeAlD
Sorafenib—ABCG2—lymph node—stomach cancer	5.38e-05	0.000935	CbGeAlD
Sorafenib—CYP2D6—endocrine gland—stomach cancer	5.34e-05	0.000927	CbGeAlD
Sorafenib—Arthralgia—Capecitabine—stomach cancer	5.02e-05	0.000588	CcSEcCtD
Sorafenib—Myalgia—Capecitabine—stomach cancer	5.02e-05	0.000588	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	4.98e-05	0.000584	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—stomach cancer	4.98e-05	0.000583	CcSEcCtD
Sorafenib—Hepatobiliary disease—Epirubicin—stomach cancer	4.97e-05	0.000582	CcSEcCtD
Sorafenib—Anaphylactic shock—Docetaxel—stomach cancer	4.97e-05	0.000582	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—stomach cancer	4.96e-05	0.000581	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—stomach cancer	4.94e-05	0.000579	CcSEcCtD
Sorafenib—Infection—Docetaxel—stomach cancer	4.94e-05	0.000578	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—stomach cancer	4.93e-05	0.000578	CcSEcCtD
Sorafenib—Diarrhoea—Irinotecan—stomach cancer	4.92e-05	0.000576	CcSEcCtD
Sorafenib—Dry mouth—Capecitabine—stomach cancer	4.91e-05	0.000575	CcSEcCtD
Sorafenib—CYP3A4—liver—stomach cancer	4.89e-05	0.00085	CbGeAlD
Sorafenib—Pneumonia—Doxorubicin—stomach cancer	4.89e-05	0.000573	CcSEcCtD
Sorafenib—Shock—Docetaxel—stomach cancer	4.89e-05	0.000573	CcSEcCtD
Sorafenib—Nervous system disorder—Docetaxel—stomach cancer	4.87e-05	0.000571	CcSEcCtD
Sorafenib—Pruritus—Fluorouracil—stomach cancer	4.87e-05	0.000571	CcSEcCtD
Sorafenib—Thrombocytopenia—Docetaxel—stomach cancer	4.87e-05	0.00057	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—stomach cancer	4.86e-05	0.00057	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—stomach cancer	4.86e-05	0.00057	CcSEcCtD
Sorafenib—Skin disorder—Docetaxel—stomach cancer	4.83e-05	0.000565	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—stomach cancer	4.82e-05	0.000565	CcSEcCtD
Sorafenib—CYP2D6—liver—stomach cancer	4.81e-05	0.000836	CbGeAlD
Sorafenib—Renal failure—Doxorubicin—stomach cancer	4.78e-05	0.00056	CcSEcCtD
Sorafenib—Infection—Capecitabine—stomach cancer	4.78e-05	0.00056	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—stomach cancer	4.77e-05	0.000558	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—stomach cancer	4.77e-05	0.000558	CcSEcCtD
Sorafenib—Dizziness—Irinotecan—stomach cancer	4.75e-05	0.000557	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—stomach cancer	4.74e-05	0.000556	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—stomach cancer	4.74e-05	0.000555	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—stomach cancer	4.74e-05	0.000555	CcSEcCtD
Sorafenib—Anorexia—Docetaxel—stomach cancer	4.74e-05	0.000555	CcSEcCtD
Sorafenib—Shock—Capecitabine—stomach cancer	4.73e-05	0.000555	CcSEcCtD
Sorafenib—Nervous system disorder—Capecitabine—stomach cancer	4.72e-05	0.000553	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—stomach cancer	4.72e-05	0.000553	CcSEcCtD
Sorafenib—Diarrhoea—Fluorouracil—stomach cancer	4.71e-05	0.000552	CcSEcCtD
Sorafenib—Thrombocytopenia—Capecitabine—stomach cancer	4.71e-05	0.000552	CcSEcCtD
Sorafenib—ABCB1—lymphoid tissue—stomach cancer	4.71e-05	0.000817	CbGeAlD
Sorafenib—Tinnitus—Methotrexate—stomach cancer	4.7e-05	0.000551	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—stomach cancer	4.68e-05	0.000548	CcSEcCtD
Sorafenib—Skin disorder—Capecitabine—stomach cancer	4.67e-05	0.000547	CcSEcCtD
Sorafenib—Urinary tract disorder—Epirubicin—stomach cancer	4.66e-05	0.000546	CcSEcCtD
Sorafenib—ABCB1—digestive system—stomach cancer	4.65e-05	0.000807	CbGeAlD
Sorafenib—Connective tissue disorder—Epirubicin—stomach cancer	4.64e-05	0.000543	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—stomach cancer	4.63e-05	0.000542	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—stomach cancer	4.6e-05	0.000539	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—stomach cancer	4.59e-05	0.000537	CcSEcCtD
Sorafenib—Anorexia—Capecitabine—stomach cancer	4.59e-05	0.000537	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—stomach cancer	4.57e-05	0.000536	CcSEcCtD
Sorafenib—Vomiting—Irinotecan—stomach cancer	4.57e-05	0.000535	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—stomach cancer	4.55e-05	0.000533	CcSEcCtD
Sorafenib—Dizziness—Fluorouracil—stomach cancer	4.55e-05	0.000533	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—stomach cancer	4.54e-05	0.000532	CcSEcCtD
Sorafenib—Rash—Irinotecan—stomach cancer	4.53e-05	0.000531	CcSEcCtD
Sorafenib—Dermatitis—Irinotecan—stomach cancer	4.53e-05	0.000531	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Docetaxel—stomach cancer	4.53e-05	0.00053	CcSEcCtD
Sorafenib—Headache—Irinotecan—stomach cancer	4.5e-05	0.000528	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—stomach cancer	4.46e-05	0.000523	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—stomach cancer	4.46e-05	0.000522	CcSEcCtD
Sorafenib—Dyspnoea—Docetaxel—stomach cancer	4.43e-05	0.000519	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—stomach cancer	4.42e-05	0.000517	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—stomach cancer	4.4e-05	0.000515	CcSEcCtD
Sorafenib—Erythema—Methotrexate—stomach cancer	4.39e-05	0.000514	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—stomach cancer	4.39e-05	0.000514	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—stomach cancer	4.39e-05	0.000514	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Capecitabine—stomach cancer	4.38e-05	0.000514	CcSEcCtD
Sorafenib—Flushing—Epirubicin—stomach cancer	4.38e-05	0.000513	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—stomach cancer	4.38e-05	0.000513	CcSEcCtD
Sorafenib—Vomiting—Fluorouracil—stomach cancer	4.38e-05	0.000513	CcSEcCtD
Sorafenib—Dyspepsia—Docetaxel—stomach cancer	4.37e-05	0.000512	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—stomach cancer	4.37e-05	0.000511	CcSEcCtD
Sorafenib—Rash—Fluorouracil—stomach cancer	4.34e-05	0.000509	CcSEcCtD
Sorafenib—Dermatitis—Fluorouracil—stomach cancer	4.34e-05	0.000508	CcSEcCtD
Sorafenib—Decreased appetite—Docetaxel—stomach cancer	4.32e-05	0.000506	CcSEcCtD
Sorafenib—Headache—Fluorouracil—stomach cancer	4.31e-05	0.000505	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—stomach cancer	4.31e-05	0.000505	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—stomach cancer	4.3e-05	0.000503	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Docetaxel—stomach cancer	4.29e-05	0.000503	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—stomach cancer	4.29e-05	0.000503	CcSEcCtD
Sorafenib—Dyspnoea—Capecitabine—stomach cancer	4.29e-05	0.000503	CcSEcCtD
Sorafenib—ABCB1—bone marrow—stomach cancer	4.29e-05	0.000744	CbGeAlD
Sorafenib—Fatigue—Docetaxel—stomach cancer	4.28e-05	0.000502	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—stomach cancer	4.28e-05	0.000501	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—stomach cancer	4.28e-05	0.000501	CcSEcCtD
Sorafenib—Nausea—Irinotecan—stomach cancer	4.27e-05	0.0005	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—stomach cancer	4.26e-05	0.000499	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—stomach cancer	4.25e-05	0.000498	CcSEcCtD
Sorafenib—Constipation—Docetaxel—stomach cancer	4.25e-05	0.000498	CcSEcCtD
Sorafenib—Pain—Docetaxel—stomach cancer	4.25e-05	0.000498	CcSEcCtD
Sorafenib—Dyspepsia—Capecitabine—stomach cancer	4.24e-05	0.000496	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—stomach cancer	4.22e-05	0.000494	CcSEcCtD
Sorafenib—Decreased appetite—Capecitabine—stomach cancer	4.18e-05	0.00049	CcSEcCtD
Sorafenib—Alopecia—Epirubicin—stomach cancer	4.17e-05	0.000488	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Capecitabine—stomach cancer	4.15e-05	0.000487	CcSEcCtD
Sorafenib—Fatigue—Capecitabine—stomach cancer	4.15e-05	0.000486	CcSEcCtD
Sorafenib—Mental disorder—Epirubicin—stomach cancer	4.13e-05	0.000484	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—stomach cancer	4.13e-05	0.000484	CcSEcCtD
Sorafenib—Pain—Capecitabine—stomach cancer	4.11e-05	0.000482	CcSEcCtD
Sorafenib—Constipation—Capecitabine—stomach cancer	4.11e-05	0.000482	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—stomach cancer	4.11e-05	0.000481	CcSEcCtD
Sorafenib—Erythema—Epirubicin—stomach cancer	4.11e-05	0.000481	CcSEcCtD
Sorafenib—Nausea—Fluorouracil—stomach cancer	4.09e-05	0.000479	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—stomach cancer	4.07e-05	0.000477	CcSEcCtD
Sorafenib—Gastrointestinal pain—Docetaxel—stomach cancer	4.06e-05	0.000476	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—stomach cancer	4.06e-05	0.000475	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—stomach cancer	4.05e-05	0.000475	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—stomach cancer	4.05e-05	0.000475	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—stomach cancer	4.02e-05	0.000471	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—stomach cancer	3.96e-05	0.000464	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—stomach cancer	3.95e-05	0.000463	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—stomach cancer	3.94e-05	0.000462	CcSEcCtD
Sorafenib—Gastrointestinal pain—Capecitabine—stomach cancer	3.93e-05	0.000461	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—stomach cancer	3.93e-05	0.000461	CcSEcCtD
Sorafenib—Abdominal pain—Docetaxel—stomach cancer	3.93e-05	0.00046	CcSEcCtD
Sorafenib—Body temperature increased—Docetaxel—stomach cancer	3.93e-05	0.00046	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—stomach cancer	3.93e-05	0.00046	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—stomach cancer	3.9e-05	0.000457	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—stomach cancer	3.86e-05	0.000452	CcSEcCtD
Sorafenib—ABCB1—endocrine gland—stomach cancer	3.84e-05	0.000667	CbGeAlD
Sorafenib—Cough—Methotrexate—stomach cancer	3.83e-05	0.000449	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—stomach cancer	3.82e-05	0.000448	CcSEcCtD
Sorafenib—Urticaria—Capecitabine—stomach cancer	3.82e-05	0.000448	CcSEcCtD
Sorafenib—Abdominal pain—Capecitabine—stomach cancer	3.8e-05	0.000446	CcSEcCtD
Sorafenib—Body temperature increased—Capecitabine—stomach cancer	3.8e-05	0.000446	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—stomach cancer	3.8e-05	0.000445	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—stomach cancer	3.8e-05	0.000445	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—stomach cancer	3.8e-05	0.000445	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—stomach cancer	3.74e-05	0.000438	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—stomach cancer	3.74e-05	0.000438	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—stomach cancer	3.72e-05	0.000436	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	3.71e-05	0.000435	CcSEcCtD
Sorafenib—Syncope—Epirubicin—stomach cancer	3.68e-05	0.000431	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—stomach cancer	3.68e-05	0.000431	CcSEcCtD
Sorafenib—Hypersensitivity—Docetaxel—stomach cancer	3.66e-05	0.000429	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—stomach cancer	3.65e-05	0.000428	CcSEcCtD
Sorafenib—Loss of consciousness—Epirubicin—stomach cancer	3.61e-05	0.000423	CcSEcCtD
Sorafenib—Cough—Epirubicin—stomach cancer	3.58e-05	0.00042	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—stomach cancer	3.58e-05	0.00042	CcSEcCtD
Sorafenib—Asthenia—Docetaxel—stomach cancer	3.57e-05	0.000418	CcSEcCtD
Sorafenib—Infection—Methotrexate—stomach cancer	3.56e-05	0.000417	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—stomach cancer	3.55e-05	0.000415	CcSEcCtD
Sorafenib—Hypersensitivity—Capecitabine—stomach cancer	3.55e-05	0.000415	CcSEcCtD
Sorafenib—Pruritus—Docetaxel—stomach cancer	3.52e-05	0.000412	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—stomach cancer	3.51e-05	0.000411	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—stomach cancer	3.51e-05	0.000411	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—stomach cancer	3.51e-05	0.000411	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—stomach cancer	3.5e-05	0.00041	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—stomach cancer	3.5e-05	0.00041	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—stomach cancer	3.48e-05	0.000408	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	3.47e-05	0.000407	CcSEcCtD
Sorafenib—ABCB1—liver—stomach cancer	3.46e-05	0.000601	CbGeAlD
Sorafenib—Asthenia—Capecitabine—stomach cancer	3.45e-05	0.000404	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—stomach cancer	3.42e-05	0.000401	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—stomach cancer	3.41e-05	0.0004	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—stomach cancer	3.41e-05	0.000399	CcSEcCtD
Sorafenib—Pruritus—Capecitabine—stomach cancer	3.4e-05	0.000399	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—stomach cancer	3.4e-05	0.000398	CcSEcCtD
Sorafenib—Diarrhoea—Docetaxel—stomach cancer	3.4e-05	0.000398	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—stomach cancer	3.35e-05	0.000393	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—stomach cancer	3.34e-05	0.000391	CcSEcCtD
Sorafenib—Infection—Epirubicin—stomach cancer	3.33e-05	0.00039	CcSEcCtD
Sorafenib—Cough—Doxorubicin—stomach cancer	3.32e-05	0.000388	CcSEcCtD
Sorafenib—Shock—Epirubicin—stomach cancer	3.3e-05	0.000386	CcSEcCtD
Sorafenib—Diarrhoea—Capecitabine—stomach cancer	3.29e-05	0.000386	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—stomach cancer	3.29e-05	0.000385	CcSEcCtD
Sorafenib—Dizziness—Docetaxel—stomach cancer	3.29e-05	0.000385	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—stomach cancer	3.28e-05	0.000384	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—stomach cancer	3.28e-05	0.000384	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—stomach cancer	3.26e-05	0.000382	CcSEcCtD
Sorafenib—Skin disorder—Epirubicin—stomach cancer	3.26e-05	0.000381	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—stomach cancer	3.24e-05	0.000379	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—stomach cancer	3.24e-05	0.000379	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	3.21e-05	0.000376	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—stomach cancer	3.2e-05	0.000374	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—stomach cancer	3.19e-05	0.000374	CcSEcCtD
Sorafenib—Dizziness—Capecitabine—stomach cancer	3.18e-05	0.000373	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—stomach cancer	3.16e-05	0.000371	CcSEcCtD
Sorafenib—Vomiting—Docetaxel—stomach cancer	3.16e-05	0.00037	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—stomach cancer	3.15e-05	0.000369	CcSEcCtD
Sorafenib—Rash—Docetaxel—stomach cancer	3.13e-05	0.000367	CcSEcCtD
Sorafenib—Dermatitis—Docetaxel—stomach cancer	3.13e-05	0.000367	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—stomach cancer	3.11e-05	0.000365	CcSEcCtD
Sorafenib—Headache—Docetaxel—stomach cancer	3.11e-05	0.000365	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—stomach cancer	3.1e-05	0.000363	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—stomach cancer	3.09e-05	0.000362	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—stomach cancer	3.09e-05	0.000362	CcSEcCtD
Sorafenib—Infection—Doxorubicin—stomach cancer	3.08e-05	0.000361	CcSEcCtD
Sorafenib—Pain—Methotrexate—stomach cancer	3.06e-05	0.000359	CcSEcCtD
Sorafenib—Vomiting—Capecitabine—stomach cancer	3.06e-05	0.000358	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—stomach cancer	3.05e-05	0.000358	CcSEcCtD
Sorafenib—Shock—Doxorubicin—stomach cancer	3.05e-05	0.000357	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—stomach cancer	3.04e-05	0.000356	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—stomach cancer	3.04e-05	0.000356	CcSEcCtD
Sorafenib—Rash—Capecitabine—stomach cancer	3.03e-05	0.000355	CcSEcCtD
Sorafenib—Dermatitis—Capecitabine—stomach cancer	3.03e-05	0.000355	CcSEcCtD
Sorafenib—Headache—Capecitabine—stomach cancer	3.01e-05	0.000353	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—stomach cancer	3.01e-05	0.000353	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—stomach cancer	2.99e-05	0.00035	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—stomach cancer	2.96e-05	0.000346	CcSEcCtD
Sorafenib—Nausea—Docetaxel—stomach cancer	2.95e-05	0.000346	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—stomach cancer	2.95e-05	0.000346	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—stomach cancer	2.93e-05	0.000343	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—stomach cancer	2.91e-05	0.000341	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—stomach cancer	2.89e-05	0.000339	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—stomach cancer	2.89e-05	0.000339	CcSEcCtD
Sorafenib—Constipation—Epirubicin—stomach cancer	2.87e-05	0.000336	CcSEcCtD
Sorafenib—Pain—Epirubicin—stomach cancer	2.87e-05	0.000336	CcSEcCtD
Sorafenib—Nausea—Capecitabine—stomach cancer	2.86e-05	0.000335	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—stomach cancer	2.85e-05	0.000333	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—stomach cancer	2.83e-05	0.000332	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—stomach cancer	2.83e-05	0.000332	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—stomach cancer	2.83e-05	0.000331	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—stomach cancer	2.77e-05	0.000324	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—stomach cancer	2.74e-05	0.000321	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—stomach cancer	2.73e-05	0.00032	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—stomach cancer	2.7e-05	0.000316	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—stomach cancer	2.68e-05	0.000314	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—stomach cancer	2.67e-05	0.000313	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—stomach cancer	2.66e-05	0.000312	CcSEcCtD
Sorafenib—ABCB1—lymph node—stomach cancer	2.66e-05	0.000461	CbGeAlD
Sorafenib—Pain—Doxorubicin—stomach cancer	2.65e-05	0.000311	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—stomach cancer	2.65e-05	0.000311	CcSEcCtD
Sorafenib—Abdominal pain—Epirubicin—stomach cancer	2.65e-05	0.00031	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—stomach cancer	2.65e-05	0.00031	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—stomach cancer	2.64e-05	0.000309	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—stomach cancer	2.57e-05	0.000301	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—stomach cancer	2.54e-05	0.000297	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—stomach cancer	2.53e-05	0.000297	CcSEcCtD
Sorafenib—Hypersensitivity—Epirubicin—stomach cancer	2.47e-05	0.000289	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—stomach cancer	2.46e-05	0.000289	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—stomach cancer	2.45e-05	0.000287	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—stomach cancer	2.45e-05	0.000287	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—stomach cancer	2.45e-05	0.000287	CcSEcCtD
Sorafenib—Asthenia—Epirubicin—stomach cancer	2.41e-05	0.000282	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—stomach cancer	2.37e-05	0.000278	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—stomach cancer	2.37e-05	0.000277	CcSEcCtD
Sorafenib—Diarrhoea—Epirubicin—stomach cancer	2.29e-05	0.000269	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—stomach cancer	2.29e-05	0.000268	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—stomach cancer	2.28e-05	0.000267	CcSEcCtD
Sorafenib—Rash—Methotrexate—stomach cancer	2.26e-05	0.000265	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—stomach cancer	2.26e-05	0.000264	CcSEcCtD
Sorafenib—Headache—Methotrexate—stomach cancer	2.24e-05	0.000263	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—stomach cancer	2.23e-05	0.000261	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—stomach cancer	2.22e-05	0.00026	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—stomach cancer	2.19e-05	0.000257	CcSEcCtD
Sorafenib—Vomiting—Epirubicin—stomach cancer	2.13e-05	0.00025	CcSEcCtD
Sorafenib—Nausea—Methotrexate—stomach cancer	2.13e-05	0.000249	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—stomach cancer	2.12e-05	0.000249	CcSEcCtD
Sorafenib—Rash—Epirubicin—stomach cancer	2.11e-05	0.000248	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—stomach cancer	2.11e-05	0.000247	CcSEcCtD
Sorafenib—Headache—Epirubicin—stomach cancer	2.1e-05	0.000246	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—stomach cancer	2.05e-05	0.00024	CcSEcCtD
Sorafenib—Nausea—Epirubicin—stomach cancer	1.99e-05	0.000233	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—stomach cancer	1.97e-05	0.000231	CcSEcCtD
Sorafenib—Rash—Doxorubicin—stomach cancer	1.96e-05	0.000229	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—stomach cancer	1.95e-05	0.000229	CcSEcCtD
Sorafenib—Headache—Doxorubicin—stomach cancer	1.94e-05	0.000228	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—stomach cancer	1.84e-05	0.000216	CcSEcCtD
Sorafenib—CYP2D6—Metabolism—HMOX1—stomach cancer	6.49e-07	6.08e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—JUN—stomach cancer	6.49e-07	6.08e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	6.49e-07	6.07e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—stomach cancer	6.48e-07	6.07e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HMOX1—stomach cancer	6.44e-07	6.02e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTM1—stomach cancer	6.42e-07	6.01e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—stomach cancer	6.36e-07	5.95e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—PIK3CA—stomach cancer	6.35e-07	5.95e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SERPINE1—stomach cancer	6.34e-07	5.94e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—stomach cancer	6.34e-07	5.93e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—stomach cancer	6.33e-07	5.93e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PIK3CA—stomach cancer	6.32e-07	5.92e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—stomach cancer	6.32e-07	5.91e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—stomach cancer	6.31e-07	5.91e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—stomach cancer	6.29e-07	5.89e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1A—stomach cancer	6.29e-07	5.89e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK3—stomach cancer	6.29e-07	5.89e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK3—stomach cancer	6.29e-07	5.89e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—stomach cancer	6.28e-07	5.88e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—stomach cancer	6.27e-07	5.87e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STAT3—stomach cancer	6.25e-07	5.85e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—stomach cancer	6.24e-07	5.84e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—stomach cancer	6.23e-07	5.83e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—stomach cancer	6.23e-07	5.83e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—stomach cancer	6.22e-07	5.83e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—stomach cancer	6.22e-07	5.82e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—stomach cancer	6.21e-07	5.81e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTT1—stomach cancer	6.21e-07	5.81e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—stomach cancer	6.2e-07	5.81e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—stomach cancer	6.2e-07	5.8e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—JUN—stomach cancer	6.19e-07	5.79e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ERCC2—stomach cancer	6.18e-07	5.79e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—stomach cancer	6.18e-07	5.79e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK8—stomach cancer	6.14e-07	5.75e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2A6—stomach cancer	6.14e-07	5.74e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—stomach cancer	6.14e-07	5.74e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TYMS—stomach cancer	6.12e-07	5.73e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RHOA—stomach cancer	6.12e-07	5.73e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—stomach cancer	6.12e-07	5.73e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—stomach cancer	6.12e-07	5.73e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—stomach cancer	6.11e-07	5.72e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—stomach cancer	6.1e-07	5.71e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—stomach cancer	6.09e-07	5.7e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1B—stomach cancer	6.08e-07	5.69e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TYMS—stomach cancer	6.07e-07	5.68e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—stomach cancer	6.07e-07	5.68e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—stomach cancer	6.06e-07	5.67e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—stomach cancer	6.05e-07	5.66e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ERCC2—stomach cancer	6.04e-07	5.65e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—stomach cancer	6.02e-07	5.64e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CAV1—stomach cancer	6.01e-07	5.62e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1A—stomach cancer	6e-07	5.62e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—stomach cancer	6e-07	5.61e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOA1—stomach cancer	5.99e-07	5.61e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK1—stomach cancer	5.99e-07	5.6e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK1—stomach cancer	5.99e-07	5.6e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—stomach cancer	5.98e-07	5.6e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—stomach cancer	5.98e-07	5.6e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKR1C3—stomach cancer	5.97e-07	5.59e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK3—stomach cancer	5.97e-07	5.59e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK3—stomach cancer	5.95e-07	5.57e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—stomach cancer	5.93e-07	5.55e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—stomach cancer	5.92e-07	5.54e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK8—stomach cancer	5.86e-07	5.48e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—stomach cancer	5.85e-07	5.48e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO1—stomach cancer	5.82e-07	5.45e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—stomach cancer	5.81e-07	5.44e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—stomach cancer	5.81e-07	5.43e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—stomach cancer	5.8e-07	5.43e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—stomach cancer	5.79e-07	5.42e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—JUN—stomach cancer	5.79e-07	5.42e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—stomach cancer	5.77e-07	5.4e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—stomach cancer	5.76e-07	5.39e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	5.74e-07	5.37e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—stomach cancer	5.71e-07	5.34e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ERCC2—stomach cancer	5.69e-07	5.32e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPP2R1A—stomach cancer	5.68e-07	5.32e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK1—stomach cancer	5.68e-07	5.32e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—stomach cancer	5.68e-07	5.32e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—stomach cancer	5.67e-07	5.31e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—stomach cancer	5.67e-07	5.31e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK1—stomach cancer	5.67e-07	5.3e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—stomach cancer	5.66e-07	5.3e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—stomach cancer	5.66e-07	5.3e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—stomach cancer	5.65e-07	5.29e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—stomach cancer	5.65e-07	5.29e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—stomach cancer	5.65e-07	5.29e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ERCC2—stomach cancer	5.64e-07	5.28e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—stomach cancer	5.64e-07	5.28e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—stomach cancer	5.63e-07	5.27e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—stomach cancer	5.61e-07	5.26e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—stomach cancer	5.61e-07	5.25e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—stomach cancer	5.61e-07	5.25e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—stomach cancer	5.6e-07	5.24e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTP1—stomach cancer	5.58e-07	5.22e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—stomach cancer	5.57e-07	5.22e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—stomach cancer	5.52e-07	5.17e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—stomach cancer	5.5e-07	5.15e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—stomach cancer	5.48e-07	5.13e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK8—stomach cancer	5.47e-07	5.12e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—stomach cancer	5.41e-07	5.06e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—stomach cancer	5.41e-07	5.06e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—stomach cancer	5.37e-07	5.03e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—stomach cancer	5.36e-07	5.02e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—stomach cancer	5.36e-07	5.02e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK3—stomach cancer	5.36e-07	5.02e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAV1—stomach cancer	5.36e-07	5.02e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—stomach cancer	5.35e-07	5.01e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—stomach cancer	5.35e-07	5.01e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOA1—stomach cancer	5.35e-07	5.01e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—stomach cancer	5.35e-07	5e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—stomach cancer	5.34e-07	5e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—stomach cancer	5.33e-07	4.99e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—stomach cancer	5.3e-07	4.96e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—stomach cancer	5.28e-07	4.94e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—stomach cancer	5.28e-07	4.94e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1B—stomach cancer	5.25e-07	4.91e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—stomach cancer	5.24e-07	4.91e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAV1—stomach cancer	5.23e-07	4.9e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOA1—stomach cancer	5.22e-07	4.89e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—stomach cancer	5.22e-07	4.88e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—stomach cancer	5.22e-07	4.88e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—stomach cancer	5.19e-07	4.86e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—stomach cancer	5.19e-07	4.86e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TYMS—stomach cancer	5.18e-07	4.85e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CD44—stomach cancer	5.16e-07	4.83e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—stomach cancer	5.12e-07	4.8e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	5.12e-07	4.79e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK3—stomach cancer	5.12e-07	4.79e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—stomach cancer	5.11e-07	4.78e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK1—stomach cancer	5.1e-07	4.78e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—stomach cancer	5.1e-07	4.78e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—stomach cancer	5.1e-07	4.77e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—stomach cancer	5.05e-07	4.73e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—stomach cancer	5.05e-07	4.73e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—stomach cancer	5.02e-07	4.7e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—stomach cancer	5.02e-07	4.7e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—stomach cancer	5e-07	4.68e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—stomach cancer	5e-07	4.68e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JUN—stomach cancer	4.99e-07	4.67e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—stomach cancer	4.99e-07	4.67e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—stomach cancer	4.98e-07	4.66e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAV1—stomach cancer	4.93e-07	4.62e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—stomach cancer	4.93e-07	4.61e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOA1—stomach cancer	4.92e-07	4.61e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—stomach cancer	4.92e-07	4.6e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—stomach cancer	4.91e-07	4.59e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAV1—stomach cancer	4.89e-07	4.58e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOA1—stomach cancer	4.88e-07	4.57e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK1—stomach cancer	4.87e-07	4.56e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—stomach cancer	4.87e-07	4.56e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—stomach cancer	4.86e-07	4.55e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—stomach cancer	4.85e-07	4.54e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—stomach cancer	4.85e-07	4.54e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—stomach cancer	4.84e-07	4.53e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—stomach cancer	4.82e-07	4.51e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ERCC2—stomach cancer	4.82e-07	4.51e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—stomach cancer	4.81e-07	4.5e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—stomach cancer	4.81e-07	4.5e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—stomach cancer	4.8e-07	4.49e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK3—stomach cancer	4.78e-07	4.48e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—stomach cancer	4.77e-07	4.46e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—stomach cancer	4.76e-07	4.45e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—stomach cancer	4.75e-07	4.44e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK8—stomach cancer	4.73e-07	4.42e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—stomach cancer	4.71e-07	4.41e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	4.67e-07	4.37e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—stomach cancer	4.65e-07	4.35e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—stomach cancer	4.6e-07	4.31e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—stomach cancer	4.6e-07	4.3e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—stomach cancer	4.6e-07	4.3e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—stomach cancer	4.6e-07	4.3e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—stomach cancer	4.56e-07	4.27e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK1—stomach cancer	4.55e-07	4.26e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—stomach cancer	4.55e-07	4.26e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—stomach cancer	4.55e-07	4.26e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—stomach cancer	4.54e-07	4.25e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—stomach cancer	4.53e-07	4.24e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—stomach cancer	4.43e-07	4.15e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	4.39e-07	4.11e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—stomach cancer	4.36e-07	4.09e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—stomach cancer	4.36e-07	4.08e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—stomach cancer	4.35e-07	4.07e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—stomach cancer	4.33e-07	4.06e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—stomach cancer	4.32e-07	4.04e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTP1—stomach cancer	4.3e-07	4.03e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—stomach cancer	4.3e-07	4.02e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—stomach cancer	4.3e-07	4.02e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—stomach cancer	4.28e-07	4.01e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—stomach cancer	4.24e-07	3.97e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—stomach cancer	4.24e-07	3.97e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—stomach cancer	4.22e-07	3.95e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAV1—stomach cancer	4.18e-07	3.91e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOA1—stomach cancer	4.17e-07	3.9e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—stomach cancer	4.15e-07	3.89e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—stomach cancer	4.14e-07	3.87e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK3—stomach cancer	4.13e-07	3.86e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—stomach cancer	4.12e-07	3.85e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—stomach cancer	4.1e-07	3.84e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—stomach cancer	4.09e-07	3.82e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—stomach cancer	4.08e-07	3.82e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—stomach cancer	4.05e-07	3.79e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—stomach cancer	4.01e-07	3.76e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TYMS—stomach cancer	4e-07	3.74e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	3.99e-07	3.74e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—stomach cancer	3.96e-07	3.7e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—stomach cancer	3.95e-07	3.7e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—stomach cancer	3.95e-07	3.7e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK1—stomach cancer	3.93e-07	3.68e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—stomach cancer	3.93e-07	3.68e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—stomach cancer	3.92e-07	3.67e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—stomach cancer	3.91e-07	3.66e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—stomach cancer	3.9e-07	3.65e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—stomach cancer	3.86e-07	3.62e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—stomach cancer	3.82e-07	3.57e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—stomach cancer	3.74e-07	3.5e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—stomach cancer	3.73e-07	3.49e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ERCC2—stomach cancer	3.72e-07	3.48e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—stomach cancer	3.71e-07	3.47e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—stomach cancer	3.71e-07	3.47e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—stomach cancer	3.7e-07	3.46e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—stomach cancer	3.67e-07	3.44e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—stomach cancer	3.65e-07	3.42e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—stomach cancer	3.62e-07	3.39e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—stomach cancer	3.5e-07	3.27e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—stomach cancer	3.5e-07	3.27e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—stomach cancer	3.41e-07	3.19e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—stomach cancer	3.41e-07	3.19e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—stomach cancer	3.38e-07	3.16e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—stomach cancer	3.3e-07	3.09e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—stomach cancer	3.3e-07	3.09e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAV1—stomach cancer	3.22e-07	3.02e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOA1—stomach cancer	3.22e-07	3.01e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—stomach cancer	3.16e-07	2.96e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—stomach cancer	3.15e-07	2.95e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—stomach cancer	3.02e-07	2.83e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—stomach cancer	3.02e-07	2.82e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—stomach cancer	2.95e-07	2.76e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—stomach cancer	2.89e-07	2.7e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—stomach cancer	2.83e-07	2.65e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—stomach cancer	2.56e-07	2.39e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—stomach cancer	2.55e-07	2.39e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—stomach cancer	2.44e-07	2.28e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—stomach cancer	2.28e-07	2.14e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—stomach cancer	2.23e-07	2.09e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—stomach cancer	2.23e-07	2.08e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—stomach cancer	2.1e-07	1.96e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—stomach cancer	2.08e-07	1.95e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—stomach cancer	1.78e-07	1.66e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—stomach cancer	1.37e-07	1.28e-06	CbGpPWpGaD
